DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,383,023 | -30.1% | 357,878 | 0.0% | 0.05% | -31.6% |
| Q2 2023 | $10,560,980 | +39.2% | 357,878 | 0.0% | 0.08% | +43.4% |
| Q1 2023 | $7,589,405 | -23.7% | 357,878 | 0.0% | 0.05% | -20.9% |
| Q4 2022 | $9,952,121 | -9.4% | 357,878 | 0.0% | 0.07% | -13.0% |
| Q3 2022 | $10,984,000 | +15.6% | 357,878 | +10.8% | 0.08% | -1.3% |
| Q2 2022 | $9,502,000 | +108.7% | 322,882 | +128.2% | 0.08% | +151.6% |
| Q1 2022 | $4,552,000 | -27.9% | 141,507 | 0.0% | 0.03% | -22.5% |
| Q4 2021 | $6,311,000 | +96.1% | 141,507 | +121.9% | 0.04% | +81.8% |
| Q3 2021 | $3,218,000 | -35.7% | 63,781 | 0.0% | 0.02% | -35.3% |
| Q2 2021 | $5,003,000 | – | 63,781 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |